This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
>= 60 years of age
Must meet the laboratory requirements per the protocol.
Female participant must not be pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 90 days after the last dose of study drug.
Female participants of childbearing potential must agree to use at least 1 protocol-specified method of birth control and male participants, if sexually active with female partner(s) of childbearing potential, must agree to practice the protocol-specified contraception.
Patients who are allergic to the study drug or drugs with similar chemical structures
Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception
Active infection
Active bleeding
The First Affiliated Hospital of Soochow University
Lead sponsor
Jining Medical University
Collaborator
The Second People's Hospital of Huai'an
Collaborator
The First Affiliated Hospital of Bengbu Medical University
Collaborator
Northern Jiangsu People's Hospital
Collaborator
Affiliated Hospital of Nantong University
Collaborator
Suzhou Hospital of Traditional Chinese Medicine
Collaborator
Taizhou University
Collaborator